{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:47:48Z","timestamp":1781246868583,"version":"3.54.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"FullHope Biomedical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12707-7","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T15:04:45Z","timestamp":1723129485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Establishment of a protocol for rapidly expanding Epstein\u2013Barr-virus-specific cytotoxic T cells with enhanced cytotoxicity"],"prefix":"10.1186","volume":"24","author":[{"given":"Chih-Hao","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shian-Ren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Yu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ren","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ling","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Mou","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"issue":"3","key":"12707_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.annonc.2022.11.011","volume":"34","author":"P Bossi","year":"2023","unstructured":"Bossi P, Chan AT, Even C, Machiels JP. clinicalguidelines@esmo.org EGCEa: ESMO-EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent\/metastatic disease. Ann Oncol. 2023;34(3):247\u201350.","journal-title":"Ann Oncol"},{"issue":"9","key":"12707_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/jjco\/hyv083","volume":"45","author":"JC Hsieh","year":"2015","unstructured":"Hsieh JC, Hsu CL, Ng SH, Wang CH, Lee KD, Lu CH, Chang YF, Hsieh RK, Yeh KH, Hsiao CH, et al. Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective phase II trial. Jpn J Clin Oncol. 2015;45(9):819\u201327.","journal-title":"Jpn J Clin Oncol"},{"key":"12707_CR3","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2147\/DDDT.S353898","volume":"16","author":"Q Yang","year":"2022","unstructured":"Yang Q, Nie YH, Cai MB, Li ZM, Zhu HB, Tan YR. Gemcitabine Combined with Cisplatin has a better effect in the treatment of Recurrent\/Metastatic Advanced Nasopharyngeal Carcinoma. Drug Des Devel Ther. 2022;16:1191\u20138.","journal-title":"Drug Des Devel Ther"},{"key":"12707_CR4","doi-asserted-by":"publisher","first-page":"175883592210962","DOI":"10.1177\/17588359221096214","volume":"14","author":"JY Xu","year":"2022","unstructured":"Xu JY, Wei XL, Wang YQ, Wang FH. Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol. 2022;14:17588359221096214.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"12707_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu Q, Li J, Zheng H, Yang S, Hua Y, Huang N, Kleeff J, Liao Q, Wu W. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer. 2023;22(1):28.","journal-title":"Mol Cancer"},{"issue":"8","key":"12707_CR6","doi-asserted-by":"publisher","first-page":"e037505","DOI":"10.1136\/bmjopen-2020-037505","volume":"10","author":"G Khan","year":"2020","unstructured":"Khan G, Fitzmaurice C, Naghavi M, Ahmed LA. Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990\u20132017. BMJ Open. 2020;10(8):e037505.","journal-title":"BMJ Open"},{"issue":"5","key":"12707_CR7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1200\/JCO.20.01709","volume":"39","author":"HE Heslop","year":"2021","unstructured":"Heslop HE, Sharma S, Rooney CM. Adoptive T-Cell therapy for Epstein-Barr Virus-related Lymphomas. J Clin Oncol. 2021;39(5):514\u201324.","journal-title":"J Clin Oncol"},{"issue":"6","key":"12707_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5732\/cjc.011.10376","volume":"31","author":"J He","year":"2012","unstructured":"He J, Tang XF, Chen QY, Mai HQ, Huang ZF, Li J, Zeng YX. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy. Chin J Cancer. 2012;31(6):287\u201394.","journal-title":"Chin J Cancer"},{"key":"12707_CR9","doi-asserted-by":"crossref","unstructured":"Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK, Beagley L, Rehan S, Crooks P, Hopkins TJ et al. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight 2018, 3(22).","DOI":"10.1172\/jci.insight.124714"},{"issue":"1","key":"12707_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cei.13640","volume":"206","author":"RS Cooper","year":"2021","unstructured":"Cooper RS, Kowalczuk A, Wilkie G, Vickers MA, Turner ML, Campbell JDM, Fraser AR. Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV-specific T cell therapy. Clin Exp Immunol. 2021;206(1):68\u201381.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"12707_CR11","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1038\/s41467-021-26097-y","volume":"12","author":"S Papathanasiou","year":"2021","unstructured":"Papathanasiou S, Markoulaki S, Blaine LJ, Leibowitz ML, Zhang CZ, Jaenisch R, Pellman D. Whole chromosome loss and genomic instability in mouse embryos after CRISPR-Cas9 genome editing. Nat Commun. 2021;12(1):5855.","journal-title":"Nat Commun"},{"issue":"3","key":"12707_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/CJI.0000000000000113","volume":"39","author":"HS Eom","year":"2016","unstructured":"Eom HS, Choi BK, Lee Y, Lee H, Yun T, Kim YH, Lee JJ, Kwon BS. Phase I clinical trial of 4-1BB-based adoptive T-Cell therapy for Epstein-Barr Virus (EBV)-positive tumors. J Immunother. 2016;39(3):140\u20138.","journal-title":"J Immunother"},{"issue":"4","key":"12707_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/CJI.0000000000000027","volume":"37","author":"BK Choi","year":"2014","unstructured":"Choi BK, Lee SC, Lee MJ, Kim YH, Kim YW, Ryu KW, Lee JH, Shin SM, Lee SH, Suzuki S, et al. 4-1BB-based isolation and expansion of CD8\u2009+\u2009T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy. J Immunother. 2014;37(4):225\u201336.","journal-title":"J Immunother"},{"issue":"5","key":"12707_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20050821","volume":"202","author":"GA Kolumam","year":"2005","unstructured":"Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202(5):637\u201350.","journal-title":"J Exp Med"},{"issue":"3","key":"12707_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cyto.2012.05.020","volume":"59","author":"KC Verbist","year":"2012","unstructured":"Verbist KC, Klonowski KD. Functions of IL-15 in anti-viral immunity: multiplicity and variety. Cytokine. 2012;59(3):467\u201378.","journal-title":"Cytokine"},{"key":"12707_CR16","doi-asserted-by":"crossref","unstructured":"Lee JM, Chen MH, Chou KY, Chao Y, Chen MH, Tsai CY. Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response. Lupus Sci Med 2022, 9(1).","DOI":"10.1136\/lupus-2022-000693"},{"key":"12707_CR17","doi-asserted-by":"publisher","first-page":"1008855","DOI":"10.3389\/fmed.2022.1008855","volume":"9","author":"JM Lee","year":"2022","unstructured":"Lee JM, Hung YP, Chou KY, Lee CY, Lin SR, Tsai YH, Lai WY, Shao YY, Hsu C, Hsu CH, et al. Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma. Front Med (Lausanne). 2022;9:1008855.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"12707_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","volume":"131","author":"C Chester","year":"2018","unstructured":"Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131(1):49\u201357.","journal-title":"Blood"},{"issue":"24","key":"12707_CR19","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/0008-5472.CAN-15-1498","volume":"75","author":"K Pilipow","year":"2015","unstructured":"Pilipow K, Roberto A, Roederer M, Waldmann TA, Mavilio D, Lugli E. IL15 and T-cell stemness in T-cell-based Cancer Immunotherapy. Cancer Res. 2015;75(24):5187\u201393.","journal-title":"Cancer Res"},{"issue":"1","key":"12707_CR20","doi-asserted-by":"publisher","first-page":"e1011934","DOI":"10.1371\/journal.ppat.1011934","volume":"20","author":"X Xu","year":"2024","unstructured":"Xu X, Zhu N, Zheng J, Peng Y, Zeng MS, Deng K, Duan C, Yuan Y. EBV abortive lytic cycle promotes nasopharyngeal carcinoma progression through recruiting monocytes and regulating their directed differentiation. PLoS Pathog. 2024;20(1):e1011934.","journal-title":"PLoS Pathog"},{"issue":"8","key":"12707_CR21","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.4049\/jimmunol.167.8.4450","volume":"167","author":"MD Catalina","year":"2001","unstructured":"Catalina MD, Sullivan JL, Bak KR, Luzuriaga K. Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection. J Immunol. 2001;167(8):4450\u20137.","journal-title":"J Immunol"},{"issue":"4","key":"12707_CR22","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1365-2567.2011.03412.x","volume":"132","author":"JP Huber","year":"2011","unstructured":"Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type I interferon. Immunology. 2011;132(4):466\u201374.","journal-title":"Immunology"},{"issue":"4","key":"12707_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri3806","volume":"15","author":"J Crouse","year":"2015","unstructured":"Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol. 2015;15(4):231\u201342.","journal-title":"Nat Rev Immunol"},{"issue":"Supplement 1","key":"12707_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2021-147274","volume":"138","author":"S Prockop","year":"2021","unstructured":"Prockop S, Mahadeo KM, Beitinjaneh A, Choquet S, Stiff P, Reshef R, Satyanarayana G, Dahiya S, Parmar H, Ye W, et al. Multicenter, Open-Label, phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood. 2021;138(Supplement 1):301\u2013301.","journal-title":"Blood"},{"issue":"10","key":"12707_CR25","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00277-021-04558-0","volume":"100","author":"WS Kim","year":"2021","unstructured":"Kim WS, Oki Y, Kim SJ, Yoon SE, Ardeshna KM, Lin Y, Ruan J, Porcu P, Brammer JE, Jacobsen ED, et al. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK\/T lymphoma: results of a multicenter study. Ann Hematol. 2021;100(10):2529\u201339.","journal-title":"Ann Hematol"},{"issue":"3","key":"12707_CR26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40291-023-00648-z","volume":"27","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Tabelecleucel: first approval. Mol Diagn Ther. 2023;27(3):425\u201331.","journal-title":"Mol Diagn Ther"},{"issue":"9","key":"12707_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jcyt.2023.04.003","volume":"25","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Lyu H, Guo R, Cao X, Feng J, Jin X, Lu W, Zhao M. Epstein\u2013Barr virus-associated cellular immunotherapy. Cytotherapy. 2023;25(9):903\u201312.","journal-title":"Cytotherapy"},{"issue":"1","key":"12707_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-018-1498-3","volume":"16","author":"R Gary","year":"2018","unstructured":"Gary R, Aigner M, Moi S, Schaffer S, Gottmann A, Maas S, Zimmermann R, Zingsem J, Strobel J, Mackensen A, et al. Clinical-grade generation of peptide-stimulated CMV\/EBV-specific T cells from G-CSF mobilized stem cell grafts. J Transl Med. 2018;16(1):124.","journal-title":"J Transl Med"},{"key":"12707_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1479-5876-7-109","volume":"7","author":"S Anguille","year":"2009","unstructured":"Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med. 2009;7:109.","journal-title":"J Transl Med"},{"issue":"1","key":"12707_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1128\/CVI.00320-07","volume":"15","author":"KU Saikh","year":"2008","unstructured":"Saikh KU, Kissner TL, Nystrom S, Ruthel G, Ulrich RG. Interleukin-15 increases vaccine efficacy through a mechanism linked to dendritic cell maturation and enhanced antibody titers. Clin Vaccine Immunol. 2008;15(1):131\u20137.","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"12707_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/cei.12816","volume":"186","author":"AN Hasan","year":"2016","unstructured":"Hasan AN, Selvakumar A, Shabrova E, Liu XR, Afridi F, Heller G, Riviere I, Sadelain M, Dupont B, O\u2019Reilly RJ. Soluble and membrane-bound interleukin (IL)-15 Ralpha\/IL-15 complexes mediate proliferation of high-avidity central memory CD8(+) T cells for adoptive immunotherapy of cancer and infections. Clin Exp Immunol. 2016;186(2):249\u201365.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"12707_CR32","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.4049\/jimmunol.1201620","volume":"190","author":"P Deshpande","year":"2013","unstructured":"Deshpande P, Cavanagh MM, Le Saux S, Singh K, Weyand CM, Goronzy JJ. IL-7- and IL-15-mediated TCR sensitization enables T cell responses to self-antigens. J Immunol. 2013;190(4):1416\u201323.","journal-title":"J Immunol"},{"issue":"9","key":"12707_CR33","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1073\/pnas.092675799","volume":"99","author":"K Liu","year":"2002","unstructured":"Liu K, Catalfamo M, Li Y, Henkart PA, Weng NP. IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8\u2009+\u2009memory T cells. Proc Natl Acad Sci U S A. 2002;99(9):6192\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"12707_CR34","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1002\/eji.201546000","volume":"45","author":"C Mathieu","year":"2015","unstructured":"Mathieu C, Beltra JC, Charpentier T, Bourbonnais S, Di Santo JP, Lamarre A, Decaluwe H. IL-2 and IL-15 regulate CD8\u2009+\u2009memory T-cell differentiation but are dispensable for protective recall responses. Eur J Immunol. 2015;45(12):3324\u201338.","journal-title":"Eur J Immunol"},{"issue":"1","key":"12707_CR35","doi-asserted-by":"publisher","first-page":"e2213222120","DOI":"10.1073\/pnas.2213222120","volume":"120","author":"Y Liu","year":"2023","unstructured":"Liu Y, Adu-Berchie K, Brockman JM, Pezone M, Zhang DKY, Zhou J, Pyrdol JW, Wang H, Wucherpfennig KW, Mooney DJ. Cytokine conjugation to enhance T cell therapy. Proc Natl Acad Sci U S A. 2023;120(1):e2213222120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"12707_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/imm.12061","volume":"139","author":"A Battaglia","year":"2013","unstructured":"Battaglia A, Buzzonetti A, Baranello C, Fanelli M, Fossati M, Catzola V, Scambia G, Fattorossi A. Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2\/transforming growth factor-beta-induced regulatory T-cell development. Immunology. 2013;139(1):109\u201320.","journal-title":"Immunology"},{"issue":"5","key":"12707_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1128\/CDLI.7.5.751-758.2000","volume":"7","author":"JI Sin","year":"2000","unstructured":"Sin JI, Kim J, Pachuk C, Weiner DB. Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and\/or Th2-type immune responses in vivo. Clin Diagn Lab Immunol. 2000;7(5):751\u20138.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"17","key":"12707_CR38","doi-asserted-by":"publisher","first-page":"8931","DOI":"10.1074\/jbc.M115.695304","volume":"291","author":"E Hong","year":"2016","unstructured":"Hong E, Usiskin IM, Bergamaschi C, Hanlon DJ, Edelson RL, Justesen S, Pavlakis GN, Flavell RA, Fahmy TM. Configuration-dependent presentation of multivalent IL-15:IL-15Ralpha enhances the Antigen-specific T cell response and anti-tumor immunity. J Biol Chem. 2016;291(17):8931\u201350.","journal-title":"J Biol Chem"},{"issue":"1","key":"12707_CR39","doi-asserted-by":"publisher","first-page":"1893500","DOI":"10.1080\/2162402X.2021.1893500","volume":"10","author":"H Xu","year":"2021","unstructured":"Xu H, Buhtoiarov IN, Guo H, Cheung NV. A novel multimeric IL15\/IL15Ralpha-Fc complex to enhance cancer immunotherapy. Oncoimmunology. 2021;10(1):1893500.","journal-title":"Oncoimmunology"},{"issue":"1","key":"12707_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.12888","volume":"154","author":"M Collin","year":"2018","unstructured":"Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018;154(1):3\u201320.","journal-title":"Immunology"},{"key":"12707_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fimmu.2013.00483","volume":"4","author":"G Schiavoni","year":"2013","unstructured":"Schiavoni G, Mattei F, Gabriele L. Type I interferons as stimulators of DC-Mediated cross-priming: impact on Anti-tumor Response. Front Immunol. 2013;4:483.","journal-title":"Front Immunol"},{"issue":"1","key":"12707_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-019-0635-8","volume":"7","author":"C Lu","year":"2019","unstructured":"Lu C, Klement JD, Ibrahim ML, Xiao W, Redd PS, Nayak-Kapoor A, Zhou G, Liu K. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. J Immunother Cancer. 2019;7(1):157.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"12707_CR43","doi-asserted-by":"publisher","first-page":"e0120274","DOI":"10.1371\/journal.pone.0120274","volume":"10","author":"SM Anthony","year":"2015","unstructured":"Anthony SM, Howard ME, Hailemichael Y, Overwijk WW, Schluns KS. Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways. PLoS ONE. 2015;10(3):e0120274.","journal-title":"PLoS ONE"},{"issue":"12","key":"12707_CR44","doi-asserted-by":"publisher","first-page":"7398","DOI":"10.4049\/jimmunol.0802982","volume":"182","author":"AG Sikora","year":"2009","unstructured":"Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, et al. IFN-alpha enhances peptide vaccine-induced CD8\u2009+\u2009T cell numbers, effector function, and antitumor activity. J Immunol. 2009;182(12):7398\u2013407.","journal-title":"J Immunol"},{"issue":"4","key":"12707_CR45","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41590-022-01152-y","volume":"23","author":"TS Sumida","year":"2022","unstructured":"Sumida TS, Dulberg S, Schupp JC, Lincoln MR, Stillwell HA, Axisa PP, Comi M, Unterman A, Kaminski N, Madi A, et al. Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat Immunol. 2022;23(4):632\u201342.","journal-title":"Nat Immunol"},{"key":"12707_CR46","doi-asserted-by":"crossref","unstructured":"Hashimoto M, Im SJ, Araki K, Ahmed R. Cytokine-mediated regulation of CD8 T-Cell responses during Acute and chronic viral infection. Cold Spring Harb Perspect Biol 2019, 11(1).","DOI":"10.1101\/cshperspect.a028464"},{"key":"12707_CR47","doi-asserted-by":"publisher","first-page":"922307","DOI":"10.3389\/fimmu.2022.922307","volume":"13","author":"CS Xia","year":"2022","unstructured":"Xia CS, Long Y, Liu Y, Alifu A, Zeng X, Liu C. IL-7 promotes the expansion of circulating CD28- cytotoxic T lymphocytes in patients with IgG4-Related Disease via the JAK signaling. Front Immunol. 2022;13:922307.","journal-title":"Front Immunol"},{"issue":"3","key":"12707_CR48","first-page":"1027","volume":"118","author":"SG Nanjappa","year":"2008","unstructured":"Nanjappa SG, Walent JH, Morre M, Suresh M. Effects of IL-7 on memory CD8 T cell homeostasis are influenced by the timing of therapy in mice. J Clin Invest. 2008;118(3):1027\u201339.","journal-title":"J Clin Invest"},{"key":"12707_CR49","doi-asserted-by":"publisher","first-page":"1139517","DOI":"10.3389\/fimmu.2023.1139517","volume":"14","author":"Y Huang","year":"2023","unstructured":"Huang Y, Zheng H, Zhu Y, Hong Y, Zha J, Lin Z, Li Z, Wang C, Fang Z, Yu X, et al. Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia. Front Immunol. 2023;14:1139517.","journal-title":"Front Immunol"},{"issue":"2","key":"12707_CR50","doi-asserted-by":"publisher","first-page":"105929","DOI":"10.1016\/j.isci.2023.105929","volume":"26","author":"H Pandit","year":"2023","unstructured":"Pandit H, Valentin A, Angel M, Deleage C, Bergamaschi C, Bear J, Sowder R, Felber BK, Pavlakis GN. Step-dose IL-7 treatment promotes systemic expansion of T cells and alters immune cell landscape in blood and lymph nodes. iScience. 2023;26(2):105929.","journal-title":"iScience"},{"issue":"1","key":"12707_CR51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12551-013-0133-z","volume":"6","author":"JL Silva-Filho","year":"2014","unstructured":"Silva-Filho JL, Caruso-Neves C, Pinheiro AAS. IL-4: an important cytokine in determining the fate of T cells. Biophys Rev. 2014;6(1):111\u20138.","journal-title":"Biophys Rev"},{"issue":"1","key":"12707_CR52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s42826-023-00183-2","volume":"39","author":"HJ Park","year":"2023","unstructured":"Park HJ, Choi EA, Choi SM, Choi YK, Lee JI, Jung KC. IL-4\/IL-4 ab complex enhances the accumulation of both antigen-specific and bystander CD8 T cells in mouse lungs infected with influenza a virus. Lab Anim Res. 2023;39(1):32.","journal-title":"Lab Anim Res"},{"issue":"7","key":"12707_CR53","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1084\/jem.20151359","volume":"213","author":"KR Renkema","year":"2016","unstructured":"Renkema KR, Lee JY, Lee YJ, Hamilton SE, Hogquist KA, Jameson SC. IL-4 sensitivity shapes the peripheral CD8\u2009+\u2009T cell pool and response to infection. J Exp Med. 2016;213(7):1319\u201329.","journal-title":"J Exp Med"},{"issue":"1","key":"12707_CR54","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jcyt.2020.08.006","volume":"23","author":"CA Lazarski","year":"2021","unstructured":"Lazarski CA, Datar AA, Reynolds EK, Keller MD, Bollard CM, Hanley PJ. Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay. Cytotherapy. 2021;23(1):65\u201376.","journal-title":"Cytotherapy"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12707-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12707-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12707-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T16:04:03Z","timestamp":1723133043000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12707-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12707"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12707-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The designation of this study complied with the Declaration of Helsinki. The study protocol was reviewed and approved by the Institutional Review Board of Far Eastern Memorial Hospital (approval code: 109007-F). All participants signed the informed consent form before blood collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"EBaT8 is patent filed by FullHope Biomedical Co., Ltd. in Taiwan (patent no I840994). Chih-Hao Fang, Ya Fang Cheng, Shian-Ren Lin, and Wan-Yu Lai are employees of FullHope Biomedical Co., Ltd. Jan-Mou Lee is the CEO of FullHope Biomedical. Co., Ltd. In addition to the above, the authors declare no other conflict of interest to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"980"}}